Barrett & Company’s Biogen BIIB Stock Holding History

Barrett & Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.5K	Hold	30	–	–	﹤0.01%	512
2025 Q4	$5.28K	Hold	30	–	–	﹤0.01%	523
2025 Q3	$4.2K	Hold	30	–	–	﹤0.01%	538
2025 Q2	$3.77K	Hold	30	–	–	﹤0.01%	552
2025 Q1	$4.11K	Hold	30	–	–	﹤0.01%	512
2024 Q4	$4.59K	Hold	30	–	–	﹤0.01%	499
2024 Q3	$5.82K	Hold	30	–	–	﹤0.01%	471
2024 Q2	$6.96K	Hold	30	–	–	﹤0.01%	460
2024 Q1	$6.47K	Hold	30	–	–	﹤0.01%	471
2023 Q4	$7.76K	Hold	30	–	–	﹤0.01%	430
2023 Q3	$7.71K	Hold	30	–	–	﹤0.01%	438
2023 Q2	$8.55K	Hold	30	–	–	0.01%	424
2023 Q1	$8.34K	Hold	30	–	–	0.01%	400
2022 Q4	$8.31K	Hold	30	–	–	0.01%	397
2022 Q3	$8.31K	Buy	+30	New	+$6.37K	0.01%	397

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barrett & Company's BIIB Position: Q1 2026 in Review

Barrett & Company held its Biogen (BIIB) position steady in Q1 2026 at 30 shares worth $5.5K. The position accounts for ﹤0.01% of the portfolio, ranked #512.

Barrett & Company first reported a position in BIIB in Q3 2022 and has held it in 15 quarters since. The position peaked at $8.55K in Q2 2023. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Barrett & Company held 30 shares of Biogen worth $5.5K as of Q1 2026.
Barrett & Company left its Biogen share count unchanged in Q1 2026.
Biogen made up ﹤0.01% of Barrett & Company's portfolio in Q1 2026, its #512 holding.
Barrett & Company first reported a position in Biogen in Q3 2022 and has held it in 15 quarters since.
Barrett & Company's Biogen position peaked at $8.55K in Q2 2023.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Barrett & Company's 13F filing for Q1 2026, filed 4 May 2026.